ALTO-101 Clinical Trial Results Update

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Apr 01 2026

0mins

ANRO-6.11%

Should l Buy ANRO?

Source: Newsfilter

Clinical Trial Results: ALTO-101 did not achieve statistical significance on primary endpoints in its Phase 2 trial for cognitive impairment associated with schizophrenia, although near-significant improvements were observed in certain EEG measures (p=0.052), indicating potential efficacy in specific subpopulations.
Priority Shift: The company has decided not to independently advance ALTO-101 and will instead prioritize resources towards ALTO-207, which is on track to initiate a Phase 2b clinical trial in the first half of 2026, targeting treatment-resistant depression.
New Formulation Development: Alto has developed a modified-release oral formulation of ALTO-101 that demonstrates improved pharmacokinetic and tolerability profiles compared to the immediate-release version, with plans to explore partnership opportunities to drive further development of this formulation.
Strong Financial Position: Alto currently holds $275 million in cash, supporting the advancement of multiple clinical programs, particularly ALTO-207, which is considered one of the most promising mechanisms in psychiatry.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ANRO?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ANRO

Wall Street analysts forecast ANRO stock price to rise

8 Analyst Rating

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 27.330

Low

25.00

Averages

35.67

High

50.00

Current: 27.330

Low

25.00

Averages

35.67

High

50.00

H.C. Wainwright

Buy

maintain

$50

2026-04-02

Reason

H.C. Wainwright

Price Target

$50

AI Analysis

2026-04-02

maintain

Buy

Reason

While Alto Neuroscience's ALTO-101 failed to meet its Phase 2 primary endpoints in cognitive impairment associated with schizophrenia, the outcome does not alter H.C. Wainwright's broader thesis, as no prior value had been assigned to the program and it will not be advanced independently, the analyst tells investors in a research note. Focus shifts to a catalyst-rich 2026, including ALTO-207 in treatment-resistant depression, ALTO-300 in major depressive disorder, and ALTO-100 in bipolar depression, with $275M in cash supporting execution across a robust precision neuropsychiatry pipeline, the firm says. H.C. Wainwright reiterates a Buy rating and $50 price target on the shares.

Baird

Brian Skorney

Outperform

NULL

downgrade

$41 -> $38

2026-04-02

Reason

Baird

Brian Skorney

Price Target

$41 -> $38

2026-04-02

downgrade

Outperform

NULL

Reason

Baird analyst Brian Skorney lowered the firm's price target on Alto Neuroscience to $38 from $41 and keeps an Outperform rating on the shares. The firm views the Phase 2 proof-of-concept trial failture evaluating ALTO-101 for the treatment of cognitive impairment associated with schizophrenia as a "bit disappointing." Schizophrenia indications are notoriously challenging so expectations were "relatively muted" into the readout, the analyst tells investors in a research note. Baird continues to see the multiple opportunities for Alto in depression as the more crucial valuation driver. The stock in premarket trading is down 11%, or $2.51, to $20.90.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ANRO

Unlock Now

About ANRO

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

US Stocks Close Mixed Amid Oil Surge and Economic Data

Apr 02 2026NASDAQ.COM

Market Fluctuations: The S&P 500 Index closed up 0.11%, while the Dow Jones Industrial Average fell 0.13%, and the Nasdaq 100 Index rose 0.11%, reflecting volatility influenced by surging oil prices and economic data.
Positive Economic Data: Weekly initial unemployment claims unexpectedly fell by 9,000 to 202,000, indicating a stronger labor market than the anticipated increase to 212,000, which could impact the Fed's interest rate policy.
Impact of Oil Surge: Crude oil prices soared over 11% due to President Trump's tougher stance on Iran, leading to sharp declines in airline and cruise line stocks, with United Airlines and Carnival both down more than 3%.
Corporate Developments: SBA Communications surged over 18% as it explores potential acquisition options, while Globalstar rose over 13% amid reports of Amazon's interest in acquiring the company, highlighting market focus on M&A activity.

Analysis of ALTO-101 Clinical Trial Failure Impact

Apr 02 2026stocktwits

ALTO-101 Trial Failure: Alto Neuroscience's ALTO-101 failed to meet key goals in its Phase 2 study, resulting in a 7% drop in stock price on Thursday, indicating weakened market confidence in its schizophrenia treatment and potential impacts on future funding capabilities.
Analyst Target Adjustments: Baird lowered Alto's price target from $41 to $38 while maintaining an 'Outperform' rating, emphasizing that the depression pipeline remains a key driver of the company's valuation, reflecting a reassessment of its potential value in the market.
Cash Reserves Support: H.C. Wainwright highlighted Alto's strong cash position of $275 million, which supports its other R&D projects despite the failure of ALTO-101, maintaining a 'Buy' rating and a $50 price target, demonstrating confidence in the company's long-term prospects.
Retail Sentiment Shift: Despite the stock's decline, retail investor sentiment on Stocktwits shifted from 'neutral' to 'bullish', indicating optimism about Alto's future potential, with the stock gaining over 20% year-to-date.

Stock Markets Pressured by Soaring Oil Prices

Apr 02 2026NASDAQ.COM

Oil Price Surge Pressures Markets: Stock indexes are under pressure as crude oil prices soar over 8% following President Trump's aggressive stance on Iran, leading to a 0.06% drop in the S&P 500, a 0.23% decline in the Dow, and a 0.20% fall in the Nasdaq 100, indicating heightened inflation concerns among investors.
Unexpected Jobless Claims Drop: Despite market pressures, initial jobless claims fell by 9,000 to 202,000, indicating a stronger labor market than anticipated, which may provide some support for stocks and alleviate investor fears of an economic slowdown.
Divergent Energy Sector Performance: Energy producers like Diamondback Energy rose over 2% due to soaring WTI prices, while airline stocks such as American Airlines and Carnival fell more than 4% as rising fuel costs cut into profits, highlighting a clear divergence across sectors.
Tech Stocks Decline: Chipmakers and AI infrastructure stocks retreated, with ARM Holdings leading the Nasdaq 100 down over 5%, reflecting waning confidence in tech stocks and potentially impacting future investment decisions.

US Stocks Plummet as Oil Prices Surge

Apr 02 2026NASDAQ.COM

Oil Price Surge: Crude oil prices soared over 13% as President Trump took a tougher stance on Iran, reaching a 3.5-week high, which not only heightened inflation fears but also pushed bond yields higher, with the 10-year T-note yield rising by 2 basis points to 4.34%.
Unemployment Claims Drop: Weekly initial unemployment claims unexpectedly fell by 9,000 to 202,000, indicating a stronger labor market than the anticipated increase to 212,000, which could provide support for the stock market amid rising inflation concerns.
Global Market Decline: Overseas stock markets are lower, with the Euro Stoxx 50 down 2.25%, China's Shanghai Composite down 0.74%, and Japan's Nikkei 225 sharply falling 2.38% from a two-week high, reflecting global economic uncertainty and investor caution.
Airline Stocks Plummet: Airline stocks are sharply lower as crude oil prices surged over 10%, raising fuel costs; United Airlines and American Airlines Group both fell more than 6%, highlighting the direct impact of rising oil prices on airline profitability.

Alto Neuroscience's Schizophrenia Drug Fails Mid-Stage Study

Apr 01 2026stocktwits

Clinical Trial Failure: Alto Neuroscience's experimental drug ALTO-101 failed to achieve statistical significance on primary electroencephalography and cognitive endpoints in a mid-stage study for schizophrenia, leading the company to discontinue its independent development.
Shift in Research Focus: Following the disappointing results for ALTO-101 in treating cognitive impairment associated with schizophrenia, the company plans to redirect its efforts towards other research programs, which may impact its future market positioning and investor confidence.
Increased Investor Attention: After the trial results were announced, ANRO shares attracted heightened investor focus, reflecting market concerns about the company's future direction and expectations for its other projects.
Market Reaction Analysis: The failure of the clinical trial may lead to short-term volatility in ANRO stock, prompting investors to closely monitor the company's subsequent research developments and strategic adjustments.